Top Markets
Coin of the day
NeuroSense Therapeutics Ltd. NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd.

NRSN
Pozycja w akcjach #31164
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical... NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Cena akcji
$0.3902
Kapitalizacja rynkowa
$13.79M
Zmiana (1 dzień)
-13.48%
Zmiana (1 rok)
-68.78%
Kraj
IL
Handel NeuroSense Therapeutics Ltd. (NRSN)

Kategoria

Historia stopy dywidendy dla NeuroSense Therapeutics Ltd. (NRSN)
Stopa dywidendy (TTM) dla NeuroSense Therapeutics Ltd. (symbol akcji: NRSN) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla NeuroSense Therapeutics Ltd. (NRSN) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji
Firma Stopa dywidendy Kraj
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH
0.48%
BE